Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty

Journal of the American College of Cardiology

Volumn 30, Issue 4, 1997, Pages 863-869

  Bertrand, Michel E ^a   McFadden, Eugène P ^a   Fruchart, Jean Charles ^a   Van Belle, Eric ^a,j   Commeau, Philippe ^b   Grollier, Gilles ^c   Bassand, Jean Pierre ^d   Machecourt, Jacques ^e   Cassagnes, Jean ^f   Mossard, Jean Marie ^g   Vacheron, André ^h   Castaigne, Alain ⁱ   Danchin, Nicolas ^j   Lablanche, Jean Marc ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b Clinique Saint Martin   (France)

^c CAEN UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY HOSPITAL OF BESANÇON   (France)

^e GRENOBLE UNIVERSITY HOSPITAL   (France)

^f UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^g UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^h Centre Universitaire   (France)

ⁱ Centre Hospitalier Universitaire   (France)

^j UNIVERSITY HOSPITAL OF NANCY   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; PRAVASTATIN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SCREENING; FEMALE; HUMAN; INTERVENTIONAL RADIOLOGY; LIPID ANALYSIS; MALE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; TREATMENT OUTCOME;

ADULT; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; COMBINED MODALITY THERAPY; CORONARY ANGIOGRAPHY; CORONARY DISEASE; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PRAVASTATIN; PROSPECTIVE STUDIES; RECURRENCE; TREATMENT OUTCOME;

EID: 9844260076     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(97)00259-3     Document Type: Article

References (27)

1. Parisi AF, Folland ED, Hartigan PA, et al. Comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease: Veterans Affairs ACME Investigators. N Engl J Med 1992;326:10-6.
2. King SB III, Lembo NJ, Weintraub WS, et al. A randomized trial comparing coronary angioplasty with coronary bypass surgery: Emory Angioplasty Versus Surgery Trial (EAST). N Engl J Med 1994;331:1044-50.
3. Hamm CW, Reimers J, Ischinger T, et al. A randomized study of coronary angioplasty compared with bypass surgery in patients with symptomatic multivessel coronary disease: German Angioplasty Bypass Surgery Investigation (GABI). N Engl J Med 1994;331:1037-43.
4. RITA Trial Participants. Coronary angioplasty versus coronary artery bypass surgery: the Randomised Intervention Treatment of Angina. Lancet 1993; 343:573-80.
5. Rodriguez A, Boullon F, Perez-Balino N, et al. Argentine randomized trial of percutaneous transluminal coronary angioplasty versus coronary artery bypass surgery in multivessel disease (ERACI): in-hospital results and 1-year follow-up (ERACI Group). J Am Coll Cardiol 1993;22:1060-7.
6. Goy JJ, Eeckhout E, Burnand B, et al. Coronary angioplasty versus left internal mammary artery grafting for isolated proximal left anterior descending artery stenosis. Lancet 1994;343:1449-53.
7. Williams DO, Baim DS, Bates E, et al. Coronary anatomic and procedural characteristics of patients randomized to coronary angioplasty in the bypass angioplasty revascularization investigation (BARI). Am J Cardiol 1995;75: 27C-33C.
8. Schaff HV, Rosen AD, Shemin RJ, et al. Clinical and operative characteristics of patients randomized to coronary artery bypass surgery in the bypass angioplasty revascularization investigation (BARI). Am J Cardiol 1995;75: 18C-26C.
9. CABRI Trial Participants. First-year results of CABRI (Coronary Angioplasty Versus Bypass Revascularisation Investigation). Lancet 1995;346: 1179-84.
10. MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 1994;344:633-8.
11. Jukema JW, Bruschke AV, van Boven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995;91:2528-40.
12. Leaf A, Jorgensen MB, Jacobs AK, et al. Do fish oils prevent restenosis after coronary angioplasty? Circulation 1994;90:2248-57.
13. Reis GJ, Boucher TM, Sipperly ME, et al. Randomised trial of fish oil for prevention of restenosis after coronary angioplasty. Lancet 1989;2:177-81.
14. Milner MR, Gallino RA, Leffingwell A, et al. Usefulness of fish oil supplements in preventing clinical evidence of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1989;64:294-9.
15. Dehmer GJ, Popma JJ, van den Berg EK, et al. Reduction in the rate of early restenosis after coronary angioplasty by a diet supplemented with n-3 fatty acids. N Engl J Med 1988;319:733-40.
16. Grigg LE, Kay TW, Valentine PA, et al. Determinants of restenosis and lack of effect of dietary supplementation with eicosapentaenoic acid on the incidence of coronary artery restenosis after angioplasty. J Am Coll Cardiol 1989;13:665-72.
17. Bairati I, Roy L, Meyer F, et al. Double-blind, randomized, controlled trial of fish oil supplements in prevention of recurrence of stenosis after coronary angioplasty. Circulation 1992;85:950-6.
18. Bertrand ME, Lablanche JM, Bauters C, et al. Discordant results of visual and quantitative estimates of stenosis severity before and after coronary angioplasty. Cathet Cardiovasc Diagn 1993;28:1-6.
19. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
20. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
21. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 1996;335:1001-9.
22. Sahni R, Maniet AR, Voci G, et al. Prevention of restenosis by lovastatin after successful coronary angioplasty. Am Heart J 1991;121:1600-8.
23. Onaka H, Hirota Y, Kita Y, et al. The effect of pravastatin on prevention of restenosis after successful percutaneous coronary angioplasty. Jpn Circ J 1994;58:100-6.
24. Weintraub WS, Boccuzzi SJ, Klein JL, et al. Lack of effect of lovastatin on restenosis after coronary angioplasty: Lovastatin Restenosis Trial Study Group. N Engl J Med 1994;331:1331-7.
25. O'Keefe JH, Stone GW, McCallister BD, et al. Lovastatin plus probucil for prevention of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1996;77:649-52.
26. Violaris AG, Melkert R, Serruys PW, et al. Influence of serum cholesterol and cholesterol subfractions after successful coronary angioplasty: a quantitative angiographic analysis of 3336 lesions. Circulation 1994;90:2267-79.
27. Roth A, Eschar Y, Keren G, et al. Serum lipids and restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1994;73: 1154-8.